NanoBio Corporation announced today that it has received a $6M grant from the Bill & Melinda Gates Foundation to support the development of a safe and effective intranasal vaccine for Respiratory Syncytial Virus (RSV).
“An RSV vaccine is a tremendous unmet need today”
RSV is a highly contagious viral disease and is one of the most common causes of bronchiolitis and pneumonia. It is the number one cause of childhood hospitalization both in the United States and around the world. Nearly all children are infected with the virus at least once by the age of 2-3 years. The disease is particularly dangerous for premature babies, children with other health conditions and the elderly. Many children develop persistent pulmonary disease and/or asthma that persists throughout adult life making them susceptible to re-infection as adults. Currently, there are no approved vaccines for RSV.
"An RSV vaccine is a tremendous unmet need today," said Ali I. Fattom, Ph.D., NanoBio's Senior Vice President of Vaccine Research & Development. "Pneumonia is a leading cause of childhood death in sub-Saharan Africa and new research suggests that RSV infection is the most common cause of viral pneumonia in parts of Africa. Our intranasal vaccine technology is unique in that it safely elicits very robust disease protection, limits the need for refrigerating vaccines and is administered without the use of needles. Each of these advantages is critical to efforts to improve health in the developing world."